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INTRODUCTION 
The relationship between vitamin D and bone quality has been 
widely researched. Vitamin D is an essential component of 
normal bone health as well as calcium/phosphate metabolism. 
Despite significant research efforts, the optimum level of 
vitamin D intake remains a topic of controversy amongst 
industry experts. For example, the Institute of Medicine 
recommends between 600 and 800 international units (IU) per 
day [1, 2]. In contrast, both the osteoporosis Canada and the 
Endocrine Society guidelines recommend a wider range of 
daily dosages (400 to 2000 IU) [3, 4]. To date, there have been 
no dose-finding studies relating vitamin D intake and bone 
health. The absence of research in this area was the major 
motivation for both the pilot study and clinical trial presented 
in this abstract. 
 
METHODS: PILOT DATA 
Participants included in this study were patients from the Pure 
North S’Energy Foundation (PNSF). There were no exclusion 
criteria for this portion of the study. All participants received a 
series of blood draws from PNSF, which determined the 
vitamin D levels in their blood. These levels were then used to 
divide participants into four different groups: low vitamin D 
(<90 mmol/L), normal vitamin D (>90 mmol/L, <175 
mmol/L), one time high vitamin D (>175 mmol/L for <6 
months), and high vitamin D (>175 mmol/L for >6 months). 
Participants were then scanned using high resolution 
peripheral quantitative computed tomography (HR-pQCT, 
Scanco Medical), to analyze their bone micro-architecture in 
both the non-dominant tibia and radius. SPSS (version 21) was 
used to analyze the differences between groups with a One-
Way ANOVA and a Tukey Post-Hoc test. Significance was set 
at p<0.05. 
 
RESULTS: PILOT DATA 
Overall, 113 participants were scanned using HR-pQCT while 
only 105 were included in the final analysis. Participants were 
on average 56 years old and 62% female. Both vitamin D 
(p<0.01) and calcium (p<0.05) were statistically different 
between groups using a One-Way ANOVA. Calcium was not 
controlled for the pilot study, but will be for the clinical trial. 
At the radius, cortical thickness (p<0.05) and cortical area 
(p<0.05) were significantly different across groups. Results 
from the Tukey Post-Hoc test showed that cortical thickness 
was significantly lower for low vitamin D compared to the 
high vitamin D group, as well as lower for the one-time high 
compared to the high vitamin D group. For cortical area, the 
one-time high group was significantly lower than the high 
vitamin D group. For the tibia, trabecular thickness was the 
only significant variable across groups (p<0.05), with low 
vitamin D being lower than the one time high vitamin D.  
 
CONCLUSIONS: PILOT DATA 
There were some bone parameters that were statistically 
different between vitamin D groups. Of these statistically 
different parameters, results differed between the radius and 
the tibia, as well as between cortical and trabecular bone. Most 
variables differed between the one-time high group and either 
the low or high groups. The only difference between the low 
and high groups was cortical thickness. This pilot data shows 
some interesting results, and the need for further, more 
controlled studies.  
 
FUTURE WORK: CLINICAL TRIAL 
This project will move forward in the form of a clinical trial 
entitled “A randomized double-blind study investigating dose-
dependent longitudinal effects of vitamin D supplementation 
on bone health”. The study will include approximately 300 
healthy men and women between the ages of 55-70 years. 
Similar to the pilot study, participants will be assigned to one 
of three vitamin D dosages and HR-pQCT will be used to 
assess bone quality. Additional methods will be used to assess 
overall skeletal, physical and mental health.  
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